Premature Ejaculation

This research investigates a new self-administered digital application designed to improve sexual health, quality of life, and psychological distress among survivors of hematopoietic stem cell transplants HCT. HCT survivors often face long-term sexual dysfunction due to complex biological, psychological, and social factors, which significantly affect their well-being and relationships. The study aims to address these challenges through a multidisciplinary approach delivered via a digital platform. Participants will be randomly assigned to either use the SHIFT digital application or receive enhanced usual care. The SHIFT app includes interactive features like gamification, survivor videos, intimacy exercises, and optional content to engage users over eight weeks. Those in the usual care group will meet with their clinicians and may be referred to specialists if needed but will not have access to the SHIFT app. During the study, participants will complete assessments measuring sexual satisfaction, function, quality of life, anxiety, and depression at various points up to 24 weeks. Researchers will monitor global satisfaction with sex at week 8 as the primary outcome. The study involves medical evaluations and tracks psychological and physical health through questionnaires and scales, aiming to evaluate the impact of the digital intervention on sexual health outcomes and overall well-being in HCT survivors.

Researchers are evaluating the impact of Transvaginal Natural Orifice Transluminal Endoscopic Surgery vNOTES compared to conventional abdominal laparoscopy CAL for benign adnexal surgery in women aged 18 to 70. The study aims to confirm that vNOTES does not negatively affect womens sexual function after surgery, addressing concerns about vaginal scarring and its effects on sexual activity. Secondary goals include assessing vNOTES efficiency, complications, and the quality of histological analysis of surgical specimens. Participants will be randomly assigned to receive either the vNOTES or CAL surgical technique for procedures such as cystectomy, oophorectomy, salpingectomy, or tubal sterilization. Both approaches involve minimally invasive surgery, with vNOTES using the vaginal route and CAL using abdominal laparoscopy. The study also examines pain, hospital stay length, patient satisfaction, and surgical complications during and up to 30 days after surgery. Women in the study will complete questionnaires before surgery and at 3 and 6 months afterward to assess sexual function, couple satisfaction, and pain during sex. Medical and general data will be collected at enrollment, during hospitalization, and one month post-surgery. The main outcomes measured include quality of sexual life and postoperative recovery, while monitoring safety and the effectiveness of both surgical methods throughout the study period.

Researchers are evaluating the effects of the web-based program OMGYES.com on sexual dysfunction in young adult female cancer survivors. This pilot trial aims to assess how feasible, acceptable, and appropriate the intervention is for this group. The study compares outcomes between participants who receive the intervention immediately and those who begin it after a period of observation. Participants will be assigned to one of two groups an immediate intervention group that starts using OMGYES.com right after enrollment, and a delayed intervention group that undergoes 5 weeks of observation before starting the program. The intervention consists of completing online educational modules at home. During the study, participants will visit the clinic every 5 weeks to complete questionnaires assessing feasibility, acceptability, and appropriateness of the intervention using standardized measures. The main outcome will be measured at the end of the 6-week study period. The trial runs through November 2026 and involves young adult female cancer survivors aged 18 to 45 years.

Researchers are studying how blood samples collected through fingerstick capillary compare to traditional venous blood samples for lab testing. This observational study aims to understand the stability of capillary blood samples under different environmental conditions and over time to support the development of lab procedures. The study addresses the need for easier, less distressing blood collection methods to expand diagnostic access and improve disease monitoring remotely. Participants may collect capillary blood themselves or have venous blood drawn by healthcare professionals at designated facilities or their homes. Capillary samples are collected via fingerstick using a lancet, with up to four samples per visit, while venous samples are collected through standard venipuncture methods. Samples are then processed and analyzed under various conditions such as temperature, humidity, light exposure, and freeze-thaw cycles to evaluate specimen stability and assay reliability. Participants provide blood samples either during a single visit or multiple visits over time until withdrawal or study end. The study includes collection of health information and consent, with compensation upon sample submission. Researchers will assess the correlation between capillary and venous samples and monitor sample stability over several days. The study is designed with minimal risk, involving routine procedures and safety monitoring, continuing until study closure or participant withdrawal.

This research aims to evaluate whether the combined use of the EXOMIND BTL-699-2 and EMSELLA HPM-6000UF devices can improve depressive symptoms, sexual function, and urinary incontinence in women who are perimenopausal or postmenopausal, aged 40 years and older, without other medical causes. The study uses a prospective, multi-center, randomized, single-blinded design with two groups to assess safety and efficacy over approximately five months. Participants are randomly assigned in a 31 ratio to either an active treatment group or a sham treatment group. The active group receives six sessions of transcranial magnetic stimulation using the BTL-699-2 device over the left dorsolateral prefrontal cortex at intensities up to 70% of their motor threshold, and six treatments with the HPM-6000UF device applied to pelvic floor muscles at intensities up to 100%. The sham group receives similar procedures at minimal intensities 1%. Treatments are spaced 3 to 7 days apart. During the study, participants complete several assessments including the Patient Health Questionnaire-9, Hamilton Depression Rating Scale, Greene Climacteric Scale, International Consultation on Incontinence Questionnaire, Female Sexual Function Index, Warwick-Edinburgh Mental Wellbeing Scale, Columbia Suicide Severity Rating Scale, Therapy Comfort Questionnaire, and Subject Satisfaction Questionnaire. These are completed at baseline, during treatment, and at follow-ups 1 month and 3 months post-treatment. Researchers monitor changes in depressive symptoms, sexual function, urinary incontinence, mental well-being, therapy comfort, satisfaction, and any treatment-related adverse events.

Researchers are evaluating SHAReClinic, a national virtual Sexual Health and Rehabilitation eClinic designed to support prostate cancer patients and their partners. This observational study aims to assess SHAReClinics impact on improving sexual function, satisfaction, relational intimacy, and overall sexual health after prostate cancer treatment. The goal is to determine SHAReClinics effectiveness across multiple cancer centers and its role in supporting long-term sexual well-being for patients and couples. Participants will have access to guided education modules and sexual health counseling through SHAReClinic as part of their usual care. The program includes a bio-medical component focused on erectile rehabilitation and a psychological component to maintain or restore intimacy. The study follows patients from before treatment through 12 months post-treatment, with virtual clinic visits scheduled at key recovery milestones, including 6 weeks, 10 weeks, 4 months, 6 months, and 12 months after treatment. Participants will complete questionnaires at baseline, 6 weeks, 6 months, and 12 months to assess sexual function, distress, intimacy, and quality of life. Each virtual clinic visit lasts about 30 minutes and involves a sexual health coach who provides support via phone or video calls. Patients can also engage with a Q&A platform and request additional check-in calls. Researchers will monitor patient satisfaction, enrollment, adherence, and data quality throughout the study, which facilitates ongoing evaluation of SHAReClinics role in sexual health rehabilitation.

Premature ejaculation PE is a common sexual dysfunction that can negatively affect quality of life and mental health, especially when anxiety disorders are also present. Researchers are working to create and test a prediction model to identify PE patients at high risk of developing anxiety disorders. This model aims to help with early treatments and improve patient care through targeted support. In this observational study, male patients diagnosed with PE will be enrolled from several clinical centers. Participants will undergo assessments including questionnaires, clinical interviews, and medical history reviews to gather data on factors that might predict anxiety disorders. Machine learning will analyze this data to build the prediction model. The models performance will then be tested using a separate group of patients to verify its accuracy and stability. Participants will be followed for about one year, with anxiety symptoms assessed within three months after PE diagnosis. Researchers will measure the prediction models accuracy, sensitivity, and specificity in identifying anxiety disorders. The study involves collecting detailed patient information through interviews and questionnaires. This research could lead to better personalized care for those at risk of anxiety related to PE.

Researchers are studying the effectiveness and safety of transcutaneous posterior tibial nerve stimulation TENS therapy in men with lifelong premature ejaculation. The trial compares TENS therapy alone, standard pharmacological treatment with dapoxetine, and a combination of both treatments. The study aims to answer whether combining these therapies improves outcomes compared to dapoxetine alone in adult men diagnosed with premature ejaculation attending clinics in Mexico City. Participants are randomly assigned to one of three groups Group 1 receives TENS therapy plus a placebo pill Group 2 receives dapoxetine 30 mg as needed plus placebo TENS therapy Group 3 receives both TENS therapy and dapoxetine. The TENS therapy involves three weekly 30-minute sessions for 12 weeks, delivering a 20 Hz electrical current with adjustable intensity based on patient tolerance. Dapoxetine or placebo pills are taken 3 to 4 hours before sexual intercourse during the 12-week intervention. During the study, participants undergo evaluations including changes in intravaginal latency time measured at 12 and 24 weeks, clinical improvement assessments, and questionnaires such as the Premature Ejaculation Profile and Global Impression of Change. Safety is monitored through reported adverse events over 24 weeks. The study lasts at least six months, including a 12-week treatment period and a 12-week follow-up to assess lasting effects.

This research aims to evaluate the effectiveness of pelvic floor therapy in managing erectile dysfunction and premature ejaculation among men experiencing these conditions. The study focuses on whether pelvic floor therapy, which includes electrostimulation, biofeedback, and therapeutic exercise, can improve erectile function and intravaginal latency time in three distinct patient groups those with premature ejaculation, erectile dysfunction, and both conditions combined. Participants will receive 24 sessions of pelvic floor therapy over 12 weeks. The therapy varies depending on whether the patient has muscular hyperactivity or hypoactivity and includes therapeutic exercises, perineal electromyographic biofeedback, and electrical stimulation. The sessions involve assessments, proprioceptive and coordination work, muscle workouts, functional training, and a final evaluation. During the study, participants will have initial and secondary pelvic floor rehabilitation consultations. Outcomes such as changes in intravaginal latency time and erectile function scores will be measured at 12 weeks, with follow-up assessments at 3 and 6 months. Researchers will also monitor side effects and other related scores throughout the study period, ensuring comprehensive evaluation of therapy impact over time.

Researchers are conducting an observational study to create a large national registry that evaluates the safety and effectiveness of treatments for men experiencing ejaculatory andor orgasmic dysfunctions. The study aims to capture important outcomes from men receiving therapy for these conditions to better understand treatment results. This collaboration with the Sexual Medicine Society of North America helps inform sexual medicine providers and encourage patient participation. Participants, including men receiving treatment and their sexual partners, will be invited by their local providers to join the study. They will complete questionnaires about their diagnosis and treatment effectiveness at the start of the study, then every three months for one year, followed by every six months for two additional years. Patient partners may also enroll and follow the same questionnaire schedule. During the study, participants will provide information through regular questionnaires over a three-year period. Researchers will use these responses to assess primary outcomes related to treatment safety and efficacy. This ongoing data collection will help build a comprehensive understanding of therapies for ejaculatory and orgasmic dysfunctions and contribute to future care improvements.